Neurotech Chief Medical Officer authors encapsulated cell technology delivery system article in Modern Retina

August 18, 2021 Cumberland, RI – The article, Encapsulated cell technology delivery of ciliary neurotrophic factor: promising treatment for macular telangiectasia type 2, was published by *Modern Retina* and written by John Pollack, MD, explores Neurotech's novel cell-based delivery system that has received Orphan Drug and Fast Track status from the FDA for MacTel type 2.

Read the full article.

About the author

John Pollack, MD is the Chief Medical Officer at Neurotech and past President of the American Society of Retina Specialists. Dr. Pollack practices at Illinois Retina Associates and is an assistant professor of ophthalmology at Rush University Medical Center in Chicago.

About Neurotech Pharmaceuticals, Inc.

Neurotech Pharmaceuticals, Inc. is a private biotechnology company developing transformational, sight saving therapeutics for the treatment of chronic eye diseases. Its patented core technology platform, Encapsulated Cell Technology (ECT), is a genetically engineered implant that enables continuous delivery of protein drugs directly into the vitreous of the eye over an extended period. We are utilizing our proprietary delivery technology platform, Encapsulated Cell Technology (ECT) to deliver therapeutic factors over an extended period for the treatment of eye diseases. Neurotech is clinically studying its lead product candidate, NT-501, in a Phase 3 program to treat the orphan disease Macular Telangiectasia (MacTel) and in a Phase 2 study to treat Glaucoma. To learn more, visit www.neurotechpharmaceuticals.com.